Last reviewed · How we verify

Salbutamol pMDI

AstraZeneca · Phase 3 active Small molecule

Salbutamol pMDI is a Short-acting beta-2 adrenergic agonist (SABA) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm. Also known as: Saltanol.

Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.

Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.

At a glance

Generic nameSalbutamol pMDI
Also known asSaltanol
SponsorAstraZeneca
Drug classShort-acting beta-2 adrenergic agonist (SABA)
TargetBeta-2 adrenergic receptor (ADRB2)
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, providing rapid symptomatic relief of bronchoconstriction. It is a short-acting beta-2 agonist (SABA) used primarily for acute relief of asthma and COPD symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Salbutamol pMDI

What is Salbutamol pMDI?

Salbutamol pMDI is a Short-acting beta-2 adrenergic agonist (SABA) drug developed by AstraZeneca, indicated for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.

How does Salbutamol pMDI work?

Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.

What is Salbutamol pMDI used for?

Salbutamol pMDI is indicated for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.

Who makes Salbutamol pMDI?

Salbutamol pMDI is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Salbutamol pMDI also known as anything else?

Salbutamol pMDI is also known as Saltanol.

What drug class is Salbutamol pMDI in?

Salbutamol pMDI belongs to the Short-acting beta-2 adrenergic agonist (SABA) class. See all Short-acting beta-2 adrenergic agonist (SABA) drugs at /class/short-acting-beta-2-adrenergic-agonist-saba.

What development phase is Salbutamol pMDI in?

Salbutamol pMDI is in Phase 3.

What are the side effects of Salbutamol pMDI?

Common side effects of Salbutamol pMDI include Tremor, Headache, Nervousness or anxiety, Palpitations, Muscle cramps, Tachycardia.

What does Salbutamol pMDI target?

Salbutamol pMDI targets Beta-2 adrenergic receptor (ADRB2) and is a Short-acting beta-2 adrenergic agonist (SABA).

Related